Regorafenib,Ipilimumab,Nivolumab
bms,bayer
['nivo', 'colorectal', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'regorafenib', 'ipilimumab', 'nivolumab', 'rectal']
 regorafenib, ipilimumab &amp; nivolumab in 3+ line #colorectalcarcinoma at #esmo22 substantial activity in mss mcrc patients without liver mets -&gt; orr 36%, mpfs 5 mo, mos nr 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision medicine